Grand challenges in biomedical physics by David Townsend et al.
SPECIALTY GRAND CHALLENGE ARTICLE
published: 12 June 2013
doi: 10.3389/fphy.2013.00001
Grand challenges in biomedical physics
David Townsend1, Zhen Cheng2, Dietmar Georg3, Wolfgang Drexler4 and Ewald Moser4,5,6*
1 Clinical Imaging Research Centre, National University of Singapore, Singapore
2 Molecular Imaging Program, Stanford University, Stanford, CA, USA
3 Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
4 Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
5 MR Center of Excellence, Medical University of Vienna, Vienna, Austria
6 Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia, PA, USA
*Correspondence: ewald.moser@meduniwien.ac.at
Edited by:
Alex Hansen, Norwegian University of Science and Technology, Norway
Recently, nature and focus of biomed-
ical physics research and development
changed rather dynamically, driven partly
by the development of new imaging
technologies, allowing increased scan-
ning rates even for lower sensitivity,
non-invasive techniques (Huang et al.,
1991; Drexler and Fujimoto, 2008;
Feinberg et al., 2010; Moser et al., 2012;
Setsompop et al., 2012). Furthermore,
hybrid imaging (PET/CT, SPECT/CT,
PET/MR, optical/photo-acoustic, MRI-
MEG, etc.) and multi-parametric imaging
(MRI, MRS, optical imaging, etc.) enables
researcher and clinicians to rapidly collect
a large amount of coherent data, in order
to better reflect/match the complexity of
animal (Pichler et al., 2010; Sauter et al.,
2010; Zhang et al., 2011; Lin et al., 2013;
Wehrl et al., in press) and human (Moser,
2010; Moser et al., 2010; Bailey et al., 2013;
Beyer and Moser, 2013; Catana et al.,
2013; Gilmore et al., 2013; Hirsch et al.,
2013; Niendorf et al., 2013; Quick et al.,
2013; Rischpler et al., 2013) tissue struc-
ture, function, and metabolism. These
novel developments help to cover a wide
range of spatio-temporal resolution and
sensitivity (Figure 1; adopted from Meikle
et al., 2005), complementing each other
in both parameters displayed, as well
as energy levels (SAR) to be applied.
Another important parameter would
be the temporal resolution, in particu-
lar relative to physiological motion, to
help increase functional contrast-to-noise
ratio by specifically reducing physiological
noise (Boubela et al., 2013). Otherwise,
group averaging may be rather limited
to extract more subtle functional differ-
ences (Biswal et al., 2010; Kalcher et al.,
2012), at least in functional MRI. Finally,
ongoing advancements in imaging and the
improved understanding of pathologies
continuously impact on the diagnosis
and (image guided) treatment of dis-
eases, especially of cancer (Bentzen, 2005).
Functional and molecular imaging have
lead to new treatment paradigms in radi-
ation oncology that have the potential to
push cancer management to the next level,
especially in combination with new beam
qualities such as particle beams. To further
explore this pool of techniques, whether
applied in single, dual or multiple modes,
or with a focus on guiding treatments, will
be one of the challenges covered by this
journal.
HYBRID IMAGING
Fusion imaging has been practiced since
the 1960s, first using manual superpo-
sition of analog images, and then, with
the advent of digital images, software-
based fusion approaches based on linear
and non-linear registration (Woods et al.,
1992). It was not until the 1990s that
the first hybrid imaging devices appeared,
the so-called “hardware” solution to image
fusion. Following the development of a
SPECT/CT prototype in 1992 (Lang et al.,
1992), a prototype PET/CT scanner for
clinical applications was developed in 1997
(Beyer et al., 2000), clinically evaluated at
UPMC, and in 2001 the first commercial
PET/CT scanner reached the market. In
parallel with the development of clinical
PET/CT, work had started on a combined
PET/MR scanner for pre-clinical (small
animal) imaging around 1995 (Shao et al.,
1997). The arrival of PET/CT in the clinic
diverted interest away from pre-clinical
PET/MR. By 2005, all new shipments of
PET scanners incorporated CT and all
major vendors of medical imaging instru-
mentation offered such a device. The
establishment of PET/CT in the clinic was
rapid (Townsend et al., 2003), and in 2004
the first commercial SPECT/CT device,
incorporating clinical CT, was delivered
to a hospital institution. Although the
adoption of SPECT/CT has been slower
than PET/CT, the appearance in the clinic
is slow but steady, with signs of an increase.
Once PET/CT and SPECT/CT were in
progress of being adopted, the attention of
researchers turned once again to PET/MR.
While PET/CT is an evolution, it led to a
revolution in imaging, especially for can-
cer. On the other hand, PET/MR required
a technical revolution to become a real-
ity (J. Czernin, private communication).
More than a decade of development of
magnetic-field insensitive photodetectors
(Pichler et al., 2006) led to some pre-
clinical prototype designs until, in 2006,
the first PET head-insert into a clinical
3 TMR scanner was evaluated (Schlemmer
et al., 2008). The design was eventually
abandoned, but in 2010 a whole body
PET/MR scanner was announced with the
capability to acquire PET and MR data
simultaneously (Delso et al., 2011). Major
vendors took different approaches and,
currently, offer simultaneous PET/MR,
and sequential acquisition with PET and
MR being acquired on separate MR and
PET scanners, either in the same room
(Zaidi et al., 2011) or in separate rooms
(von Schulthess et al., 2013). PET/MR
has therefore arrived in the clinic and
it will remain to be seen how rapidly
the technology is adopted (Bailey et al.,
2013; Beyer and Moser, 2013). The cost of
the device, uncertainty about appropriate
applications, definition of suitable proto-
cols and, of course, the already clinically
well-established PET/CT scanner are all
factors in the adoption of PET/MR, leaving
room for scientific and technical improve-
ments. In the pre-clinical domain, a few
PET/MR designs are slowly being adopted
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FIGURE 1 | Molecular imaging matrix indicating the relative position of
various invasive and non-invasive imaging techniques (adopted from
Meikle et al., 2005). Please note that the temporal resolution of the
various modalities is not included here. In such a ranking optical
techniques (seconds) would rank before MRI and PET (minutes), then MRS
and SPET (≥30min).
for animal imaging at 7 T, and one vendor
is promoting a PET/MR based on a 1 T
permanent magnet.
These are not, however, the full extent
of hybrid instrumentation. Combinations
of SPECT with MR, PET with ultrasound
and even optical with PET complement
the hybrid imaging range of devices. No
doubt in the future, there will be other
combinations that emerge, e.g., MRI-
MEG (Ilmoniemi, 2013). All these designs,
including those that are already commer-
cial realities, offer challenges to the engi-
neer and physicist, as well as opening up
new possibilities for the clinician and biol-
ogist. The field of hybrid imaging, even
including the early analog approaches is
still relatively new, and the novel advances
that have emerged in the past few years
establish this field firmly as one at the
frontier of biomedical physics.
MOLECULAR IMAGING
Molecular imaging realizes the visualiza-
tion of cellular function, cell commu-
nication, molecular target and process
in living subjects without intervening
them. It has shown great potential for
advancing numerous fields in medicine,
from basic molecular biology research
and drug development to clinical cancer
diagnosis and management of patients.
Molecular imaging has been considered
as one of the key components in modern
molecular medicine and a powerful tool
to achieve personalized medicine (James
and Gambhir, 2012). Molecular imag-
ing largely involves the use of molecular
probes for reporting molecular informa-
tion of cells and diseases. A variety of dif-
ferent molecular platforms such as small
molecules, peptides, scaffold proteins,
oligonucleotides, and nanoparticles have
been explored to discover novel molecular
probes for single or multimodality imag-
ing (He et al., 2010; Miao et al., 2011).
In order to eventually translate the
molecular probes into clinical applica-
tion and make high impact to the cur-
rent medical practice, many issues and
challenges need to be considered and
overcome. Some of them include (1)
Discovery and selection of biomarkers
with high biological importance and sig-
nificant medical applications (diagnosis,
prognosis, treatment monitoring, etc.); (2)
Understanding the advantages and limita-
tions of different molecular platforms for
clinical translation, establish new chem-
istry for probe synthesis and preparation,
keep testing novel strategies for design
new generation of probes, incorporate sig-
nal amplification, and targeted imaging
mechanisms into the probe, develop gen-
eralizable approach for facilitating probe
translation, and combine imaging and
therapy together; (3) Exploring the poten-
tial use of multimodality imaging, exam-
ine the necessity of combining different
imaging modalities for different medical
scenarios, supply well-designed and ratio-
nalized multimodality imaging probes
to the research community; (4) Realize
multiplex imaging ability through novel
imaging modalities and probes, integrate
in vitro diagnosis and pathology and
in vivo molecular imaging to achieve best
diagnosis and management of diseases;
(5) Develop new imaging modalities or
hybrid imaging modalities as mentioned
above. Besides the conventional imaging
modalities (MRI, CT, PET, SPECT, opti-
cal imaging), novel single or hybrid imag-
ing modalities such as Raman imaging,
Cerenkov luminescence imaging, X-ray
excited luminescence imaging, or X-ray
excited acoustic imaging could surpass
many traditional imaging modalities and
provide new information on diseases and
complex mechanisms (Keren et al., 2008;
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Sun et al., 2011; Xu et al., 2011; Xiang et al.,
2013).
OPTICAL IMAGING
Multi-scale, multi-resolution imaging is
recognized as the future of biomedical
and biophotonic sciences as well as med-
ical diagnosis. This requires multi-scale
three-dimensional morphologic and func-
tional imaging at different resolutions in
order to enable “morpho-functional” per-
formance, i.e., the fusion of anatomic and
functional imaging at the cellular or even
molecular resolution level. Optical imag-
ing offers low-cost, non-invasive, accurate,
rapid alternatives with use of safe (non-
ionizing) levels of optical radiation and
the potential to address global medical
needs addressing non- to minimally inva-
sive optical imaging from molecular to
(sub)cellular to individual organs, with no
gap in the arsenal of diagnostic tools for
medical end-users. Biophotonics, optical
imaging and diagnostics have offered great
promise for addressing unmet clinical
needs due to their combination of non-
invasive, real-time capture of biomed-
ical information enabling point-of-care
decisions.
Since the invention of optical (Hooke
in 1632), confocal, and multiphoton
microscopy, light-sheet microscopy, and
super resolution microscopy techniques
like STED, PALM, and STORMhave signif-
icantly enhanced the performance of this
technique (Betzig et al., 2006; Hess et al.,
2006; Rust et al., 2006; Hell, 2007). Optical
imaging mainly benefits from three funda-
mental light tissue interactions that have
initiatedan extremely broad rangeofmeth-
ods and technologies: (1) Light emission is
employed in auto fluorescence imaging,
fluorescence microscopy, bioluminescence
imaging as well as Raman spectroscopy
(Luker and Luker, 2008; Condeelis and
Weissleder, 2010; Pittet and Weissleder,
2011). (2) Light scattering is the basic
contrast mechanism in optical coherence
tomography (OCT), reflectance confocal,
and multiphoton microscopy, endoscopy
microscopy, vibrational, non-linear opti-
cal spectroscopy as well as light scattering
spectroscopy (Huang et al., 1991; Masters
and So, 1999; Sokolov et al., 2002; Drexler
and Fujimoto, 2008; Silberberg, 2009; Li
and Xie, 2011; Min et al., 2011). (3)
Light absorption is used in pulse oximetry,
opticalprojectiontomography(OPT),near
infrared spectroscopy (NIRS), diffuse opti-
cal imaging [DOI; also known as Near
Infrared Optical tomography (NIROT),
Diffuse Optical Tomography (DOT), or
Optical Diffusion Tomography (ODT)],
optical mammography, and photoacoustic
tomography/spectroscopy (Villringer and
Chance, 1997; Ntziachristos and Chance,
2001; Ntziachristos, 2010; Wang and Hu,
2012; Ntziachristos and Razansky, 2013).
Hybrid combinations of several optical
imaging techniques offermultimodal solu-
tions to diagnostic needs that exploit
the benefits of each modality. Nano-
Biophotonics promises nanoscale imag-
ing, miniaturized imaging technologies
(“imaging on a chip”), colloidal nanopar-
ticles, molecular probes as well as bio-
engineered and biointegrated phtotonic
devices (Kumar and Richards-Kortum,
2006; Pierce et al., 2008; Bardhan et al.,
2011).
In order to become more widespread
and to even more successfully translate
(multi-modal) optical imaging into clin-
ical application the following challenges
have to be overcome: (1) Insufficient “sen-
sitivity and specificity”: optical imaging
methods are very sensitive but suffer from
poor specificity, resulting in high numbers
of false positive diagnoses. Alternatively,
optical methods have high specificity, but
insufficient sensitivity, leading to missed
diagnoses. (2) Poor utility: optical imaging
systems can be difficult to use by non-
specialists, and data or images are difficult
to interpret. (3) Breadth of application:
aspects of the disease may prevent effec-
tive use of optical imaging, i.e., the lesion
is difficult to access, or is located too
deep for imaging. (4) Regulatory issues:
in certain diseases, clinically accepted pro-
cedures exist, which make introduction
and approval of novel methods diffi-
cult. (5) High costs: it is often incor-
rectly assumed that improvements from
introducing optical techniques are “incre-
mental” as opposed to “game-changing.”
Hence, the cost of new instrumentation




Progress in radiation oncology has always
been closely linked with innovations in
medical radiation physics and computer
sciences, morphological, and functional
imaging methodologies, and new insights
into the radiobiology and radiopathophys-
iology of both tumors and normal tis-
sues at the molecular, cellular, and tissue
level. During the last two decades spec-
tacular advances in medical imaging (e.g.,
hybrid imaging devices) of both anatomy
and physiology, and in medical radiation
physics (i.e., beam generation and shap-
ing, ion beam therapy) as well as in com-
puter sciences have made it possible to
define target structures and volumes of
radiotherapywith increasing precision and
to deliver radiation doses with unprece-
dented accuracy to the predefined target,
which includes the macroscopic tumor
and the region of assumed microscopic
spread.
Based on the high spatial resolution
of the morphological/anatomical imaging
data, sophisticated treatment techniques
such as intensity modulated radiother-
apy (IMRT), stereotactic radiotherapy or
even ion beam therapy can be planned
and executed (Kirisits et al., 2005; Schulz-
Ertner and Tsujii, 2007; Georg et al., 2008).
Despite the general knowledge about dose-
effect relationships for both malignant
and normal tissues (“higher doses to
the tumor are likely to result in higher
cure rates, but higher doses to normal
tissues will result in increased rates of
adverse events”), the information about
relationships between radiation response
and various dose-volume parameters is
clearly limited for the majority of organs at
risk, as is knowledge about the influence of
the spatial localization of the dose within
the organ (Bentzen et al., 2010). This is
one of the current limitations in treatment
plan optimization.
During the last decade equipment and
hybrid tools for image-guided radiother-
apy (IGRT) have been developed, such
as the linear accelerator with CT options
(Siewerdsen and Jaffray, 1999). Ongoing
developments like the hybrid MR linear
accelerator will allow visualizing struc-
tures during treatment with an outstand-
ing soft tissue contrast (Lagendijk et al.,
2008). Thus, the objective of IGRT, i.e.,
to include the time as a fourth dimen-
sion in treatment planning and delivery,
can be fully exploited. Besides geometric
accuracy and temporal variations during
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treatment delivery, the biological aspects
and their temporal variation add another
level of complexity in cancer management
(Ling et al., 2000).
Functional imaging techniques help to
define biological rather than anatomic
targets. The potential role of dynamic
contrast enhanced CT and MRI (DCE-
CT/DCE-MRI), diffusion weighted MRI
(DW-MRI), MR spectroscopy or PET
imaging is still subject of intensive research
(Padhani and Miles, 2010; van der Heide
et al., 2012). Today, only very few research
centers explore the role of functional
imaging techniques in radiation oncology.
Furthermore, functional imaging allows
selecting sub-volumes, for example poorly
oxygenated areas, for dose escalation.
The selective boosting of radio-resistant
subvolumes is called “dose painting”
(Bentzen, 2005). Although from a tech-
nological point of view various “brushes”
can be utilized, ranging from brachyther-
apy approaches to delivery methods with
high-energy photon beams or ion beams,
the concept of dose painting is currently
hampered by the challenge to extract suf-
ficient and relevant quantitative informa-
tion from functional imaging. The use of
functional diagnostic methods for radia-
tion oncology in a quantitative rather than
a qualitative manner has been coined ther-
agnostic imaging (Bentzen, 2005).
The above outlined challenges in radia-
tion oncology, both with respect to spatial
and temporal changes, and the additional
“dimension” of tumor subvolume char-
acterization becomes even more impor-
tant in the context of ion beam therapy,
which is a wide playground for research in
medical (radiation) physics (Mackay et al.,
2012; Rosenberg and Tepper, 2013).
Furthermore, the assessment of tumor
response and—even more important—
adverse effects in normal tissue are essen-
tial research topics in radiation oncol-
ogy. Early biomarkers, indicative of the
risk of an individual patient to develop
(late) side effects, might offer the opportu-
nity to judge treatment approaches. Such
“morbidity biomarkers” however, need to
be validated and established in preclinical
and clinical studies. Moreover, subvolumes
of tissue and organs related to specific
morbidity symptoms and endpoints need
to be identified, and their radiobiologi-
cal characteristics, such as dose response,
fractionation effect, time factor, and others
need to be defined (Awada and Aftimos,
2013).
In the context of biologically and image
guided adaptive radiotherapy the transla-
tion of experimental and investigational
approaches into the clinical situation and
eventually their implementation into clin-
ical routine are still major steps to be
taken. The clinical relevance of these
innovative strategies has to be validated
within sound and comprehensive settings.
Although the rationale for biologically
adaptive radiotherapy is evident (Yan et al.,
1997; Tanderup et al., 2010), there is still a
long way to go before personalized adap-
tive radiotherapy may become a standard
approach in radiation oncology.
ROBUST STATISTICS
In the statistical analysis of data originat-
ing from measurements of physiological
processes the presence of outlying obser-
vations does not only hamper the extrac-
tion of the signals of interest, but also
compromises the stability of the statistical
method used by violating the rather strict
assumptions necessary for the correctness
of these standard methods. This is cer-
tainly the case when jointly analysing com-
plex anatomical, functional, andmetabolic
data originating from the same (e.g., MRI)
or different (hybrid imaging) scanners.
Measured signal changes, ideally related
to effects of, e.g., neuronal activation are,
beside the superposition by physiologi-
cal phenomena (i.e., respiration, heart-
beat, brain pulsation, etc.), contaminated
by outliers introduced by subject move-
ment and technical artifacts. A key point
to obtain stable and reproducible results
of complex analyses performed is, there-
fore, to employ robust statistical methods
that are capable to handle the separation
of noise and the signal of interest from
functional and metabolic data even if a
significant amount of outliers is present.
For pure scientific use, either in ani-
mal models or healthy humans, averag-
ing is performed frequently across groups,
with increasing group size. However, this
approach also needs high quality single-
subject data as, otherwise, sensitivity and
specificity may be reduced in group results
or, at least, not increasing as expected
(Button et al., 2013). In any case, indi-
vidual variations in anatomy and function
may limit any group statistics. In medical
diagnosis, single-patient imaging data can-
not be matched/averaged due to further
increased variability based on individual
pathological changes. In this case, it must
be our goal to improve diagnostic imaging
tools to a point where single patient data
are of utmost quality ad specificity. Only
if this can be achieved in the future, ther-
apeutic interventions can be tailored to
such an extent that personalized medicine
will become reality. However, in our opin-
ion, there is still a long way ahead.
Education in Biomedical Physics,
although very important, will not be cov-
ered in this journal. However, Medical
Physics International, edited by S. Tabakov
and P. Sprawls and launched 2013, will
be dedicated to world-wide education in
Medical Physics (Tabakov, 2013).
FUTURE DIRECTIONS
Essentially, there seems to be growing
recognition that tissue or organ function is
the result of complex interactions between
and across various hierarchical levels of
organization, integrated at the systems
level under investigation (cf. West, 2011;
Winslow, 2011). However, before such
complex models can be developed and
tested, all advanced imaging techniques
have to be thoroughly questioned, opti-
mized and validated in order to col-
lect reliable data from single subjects or
organs. This, obviously, not only requires
machinery operating safely and smoothly,
as known for medical imaging devices,
but needs (1) a deeper understanding
of the imaging hardware, (2) full under-
standing of the imaging protocols, (3)
sufficient understanding of basic physi-
cal or chemical mechanisms leading to
signal changes and image contrast, (4)
a thorough understanding of any techni-
cal and/or physiological artifacts limiting
the performance (e.g., speed, resolution,
distortions, SNR, CNR), to help develop
(5) appropriate pre- and post-processing
strategies to further improve data qual-
ity. Furthermore, (6) techniques to han-
dle ever growing amounts of data (e.g.,
storage, backup, processing speed), (7)
appropriate data reduction techniques, as
well as (8) robust statistics when deal-
ing with huge in vivo data sets are pre-
requisites to nurture advanced modeling
strategies. This is even more important
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if data collected by different techniques
(i.e., basic contrast mechanisms) are to be
combined, whether quasi-simultaneously
or retrospectively (e.g., Beyer and Moser,
2013) and modeled adequately.
To summarize, the world of Biomedical
Physics appears rather exciting at this
time and we would like to encourage
young scientists to submit their novel
ideas, technical, and scientific work to
Frontiers in Biomedical Physics in order
to indulge into exciting scientific exchange
and cross-fertilization between physics,
basic biomedical science and medicine.
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